Deal overview
| Target | GENMAB A/S (RIGHTS TO THREE BISPECIFIC ANTIBODY PRODUCTS) |
|---|---|
| Bidder | ABBVIE INC |
| Price | £60.00 Full version or £25.00 Light version |
| Publication Date | Jun 10, 2020 |
| Abstract | On 10 June 2020, the quoted US biopharmaceutical company, AbbVie Inc. ("AbbVie"), announced that it had signed a collaboration agreement with the quoted Danish biotechnology company ("Genmab") to jointly develop and commercialise three of Genmab's early-stage investigational bispecific antibody product candidates, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and ... |
| Number of pages (Full version) | 6 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
